4142:TPE
Adimmune Corp
16,80 TWD
arrow_upward
+0,60%(+0,100) 1D
13 lis, 13:30:11 GMT+8 · TWD
search
Wszystkie symbole
| Symbol | Cena | Zmiana | Zmiana % |
|---|
insights_autoGeneruję najważniejsze statystyki dotyczące: 4142…
Otwarcie
16,85 TWD
Maks.
17,15 TWD
Min.
16,75 TWD
Kapitalizacja
7,22 mld
Śr. wol.
1,13 mln
Wolumen
724,64 tys.
Najwyższa z 52 tyg.
22,50 TWD
Minimum z 52 tyg.
15,65 TWD
Zysk na akcję
-0,34 TWD
Akcje w obiegu
235,29 mln
Liczba pracowników
564
Otwarcie
16,85 TWD
Maks.
17,15 TWD
Min.
16,75 TWD
Kapitalizacja
7,22 mld
Śr. wol.
1,13 mln
Wolumen
724,64 tys.
Najwyższa z 52 tyg.
22,50 TWD
Minimum z 52 tyg.
15,65 TWD
Zysk na akcję
-0,34 TWD
Akcje w obiegu
235,29 mln
Liczba pracowników
564
Wiadomości
Ze źródeł internetowych i od partnerskich agencji informacyjnych
ChartMill
·
1 godzinę temu
S&P 500 Top Movers for Nov. 13, 2026: Charter Communications Leads Gainers, AMD Leads Losers
MarketWatch
·
22 minuty temu
S&P 500, Nasdaq end lower as chip stocks sell off
24/7 Wall St.
·
15 minut temu
S&P 500 Closes Down 0.4% as Tech Drags and the Dow Holds Green
FOREX.com
·
2 godziny temu
S&P 500 forecast: SPX struggles for direction ahead of PPI data
Profil
Adimmune Corporation is a Taiwanese pharmaceutical company engaged in the research, development, manufacturing, and sales of medicines and vaccines for both humans and animals. Its products are supplied to both local and international markets.
Founded in 1965 and headquartered in Tanzi District, Taichung, it has a market cap of US$230 million, 564 employees and annual sales of $106 million as of 2026.
Adimmune continues to seek expansion its role in the regional pharmaceutical and vaccine industry through international collaborations.
In January 2021, Adimmune Corporation announced a partnership with Sam Chun Dang Pharm to jointly develop an injectable medication used to treat macular disease.
In July 2021, the company announced that its first overseas manufacturing site will be situated in the Special Economic Zone in East Java, Indonesia, aiming to launch clinical trials for its COVID-19 vaccine in Indonesia early 2022.
In August 2021, Adimmune Corporation signed a memorandum of understanding with Becton, Dickinson and Company to strengthen its international pharmaceutical collaboration. Wikipedia
Adimmune Corp – informacje
Prezes-
Pracownicy564
Data założenia1965
Siedziba główna-
SektorHealth Care
Branża-
Witrynaadimmune.com.tw